Stellar science. Focused care.
BRINGING IT ALL TOGETHER FOR YOU.
Stellar science. Focused care.
BRINGING IT ALL TOGETHER FOR YOU.
Stellar science. Focused care.
BRINGING IT ALL TOGETHER FOR YOU.
The StrateGIST program is investigating the safety and effectiveness of the investigational study drug, IDRX-42 (GSK6042981), for the treatment of gastrointestinal stromal tumours (GIST). IDRX-42 (GSK6042981), is designed to be a highly selective and powerful inhibitor of the KIT protein, which is over-active in many people with GIST, causing the cancer cells to grow and accumulate. There are two open and enrolling StrateGIST trials.
For adults with advanced GIST that has not been treated or has progressed after treatment
For adults with advanced GIST that has progressed while taking imatinib or who cannot tolerate imatinib
The StrateGIST program is investigating the safety and effectiveness of the study drug IDRX-42 for the treatment of gastrointestinal stromal tumours (GIST). IDRX-42 is a highly selective and powerful inhibitor of the KIT protein, which is over-active in many people with GIST, causing the cancer cells to grow and accumulate. There are two open and enrolling StrateGIST trials.
For adults with advanced GIST that has not been treated or has progressed after treatment
For adults with advanced GIST that has progressed while taking imatinib or who cannot tolerate imatinib
Interested in learning more?
Talk to your doctor for more information and click on the link below to find a StrateGIST 1 Trial site near you.
Participation in the trial is voluntary and you can choose to leave at any time.